Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial
Primary result · Diabetes relapseResult — go to the resultAdjusted hazard ratio 0.57 95% CI 0.40–0.81Authors' conclusion
A 12-week intensive intervention comprising insulin glargine/lixisenatide, metformin and lifestyle approaches can induce remission of diabetes.
Study context
- Population
- Patients with T2D on none to two diabetes medications other than insulin
- Participants
- 160 patients
- Comparison
- Intensive intervention vs standard care
- Primary endpoint
- Diabetes relapse: HbA1c ≥6.5% (48 mmol/mol) at 24 weeks or thereafter, capillary glucose ≥10 mmol/L on ≥50% of readings, or use of diabetes medications; time-to-event
Methodological detailshierarchical testing strategy
- Hierarchical testing strategy
Primary result
Diabetes relapse
Adjusted hazard ratio
0.57
95% CI 0.40–0.81
P = 0.002
Interventionvs Standard care
aHR 0.57 (95% CI 0.40–0.81); P = 0.002
As reported in the abstract
Secondary outcomes
| Outcome | Intervention | Standard care | RR for remission | |
|---|---|---|---|---|
| Complete or partial diabetes remission (HbA1c <6.5% off diabetes medications since 12 weeks) · 24 weeks | 38.0% | 19.8% | 1.92 (95% CI 1.14–3.24) | |
| Complete or partial diabetes remission · 36 weeks | 31.6% | 17.3% | 1.83 (CI 1.03–3.26) | |
| Diabetes remission · 48 weeks | 1.88 (CI 1.00–3.53) | |||
| Diabetes remission · 64 weeks | 2.05 (CI 0.98–4.29) | |||
| 0.20.5125RR for remission (log scale) |
Original publication
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial. Diabetes Obes Metab. Published 14 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →